Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29525702 | 1.00 | ERN1 (0.47) | ERN1LMNAMEN1THRBBLM | |
| SCHEMBL30037631 | 1.00 | ERN1 (0.47) | ERN1LMNAMEN1THRBBLM | |
| SCHEMBL6853865 | 0.83 | KMT2A (0.58) | ERN1LMNAMEN1THRBBLM | |
| SCHEMBL29390677 | 0.79 | TDP1 (0.36) | ERN1LMNAMEN1THRBBLM | |
| SCHEMBL898807 | 0.79 | TDP1 (0.36) | ERN1LMNAMEN1THRBBLM | |
| SCHEMBL22675468 | 0.78 | KCNJ1 (0.37) | ERN1LMNAMEN1THRBBLM | |
| SCHEMBL22675473 | 0.78 | ALDH1A1 (0.37) | ERN1LMNAMEN1THRBBLM | |
| SCHEMBL16954945 | 0.77 | MAPT (0.41) | ERN1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL6873694 | 0.77 | LMNA (0.38) | LMNASMN1; SMN2GAAMAPTHSD11B1 | |
| SCHEMBL2945596 | 0.77 | ALDH1A1 (0.38) | LMNAALDH1A1SMN1; SMN2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 687 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113264819-B | Method for rapidly synthesizing 3-bromo-2-fluorobenzaldehyde based on continuous flow reaction technology | 都创(上海)医药开发有限公司 | 2024-11-05 | — | — | CN | claimed |
| CN-118546092-A | Synthesis method of 7-bromo-1H-indazole-3-methyl formate | 南通大学 | 2024-08-27 | — | — | CN | claimed |
| CN-113264819-A | Method for rapidly synthesizing 3-bromo-2-fluorobenzaldehyde based on continuous flow reaction technology | 都创(上海)医药开发有限公司 | 2021-08-17 | — | — | CN | claimed |
| CN-109651375-A | A kind of tetrahydro quinazoline derivative and its synthetic method and application | 上海应用技术大学 | 2019-04-19 | — | — | CN | claimed |
| CN-109312618-A | For hydraulic fracturing and for the method and composition of tracer water flooding | 光谱追踪服务有限责任公司 | 2019-02-05 | — | — | CN | claimed |
| US-10017684-B2 | Method and compositions for hydraulic fracturing and for tracing formation water | SPECTRUM TRACER SERVICES, LLC (US) | 2018-07-10 | — | — | US | claimed |
| CN-108057417-A | For the modified zeolite adsorbent of benzene in Adsorption wastewater from chemical industry | 北京益清源环保科技有限公司 | 2018-05-22 | — | — | CN | claimed |
| US-20170306217-A1 | METHOD AND COMPOSITIONS FOR HYDRAULIC FRACTURING AND FOR TRACING FORMATION WATER | NCS Multistage, LLC | 2017-10-26 | — | — | US | claimed |
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-3891149-B1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2026-01-28 | — | — | EP | disclosed |
| EP-4673139-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | Sionna Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| EP-4667464-A1 | AZOLYLPYRIDINE PYRIDAZINONE AMIDE AS SOS1 INHIBITOR | Cyrus Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| US-20250339402-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | FUNDAMENTAL PHARMA GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| WO-2000066167-A1 | CONTRACEPTIVE COMPOSITIONS CONTAINING INDOLINE DERIVATIVES AND PROGESTATIONAL AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066556-A1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000066571-A1 | CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE RECEPTOR MODULATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| US-5489592-A | ALDOSE REDUCTASE INHIBITORS FOR TREATMENT OF DIABETES-RELATED DISORDERS | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1996-02-06 | — | — | US | disclosed |
| EP-0607344-A1 | 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993007109-A1 | 3,4-DIHYDRO-4-OXO-3-(PROP-2-ENYL)-1-PHTALAZINEACETIC ACIDS AND DERIVATIVES, PREPARATIONS THEREOF AND DRUGS CONTAINING SAME | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339402-A1 | EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY | TRPM4, GRM4, GRIN1 | ERN1 3222/4885LMNA 4719/4885MEN1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.